Editorial: Exosomes and exosomal miRNAs as biomarkers in infection with Mycobacterium tuberculosis

COPYRIGHT © 2023 Alipoor. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. TYPE Editorial PUBLISHED 26 July 2023 DOI 10.3389/fcimb.2023.1239739

Mtb infection leads to host immune and metabolic repatterning, which enables Mtb to perturb the autophagy and apoptosis of infected cells and maintain their nutritional and energy requirements.
This process involves the modulation of host miRNAs that control the regulatory networks associated with cell metabolism and immunity in the infected cells (Alipoor et al., 2017;Alipoor et al., 2019).
The TB-dysregulated host miRNAs may be shuttled across the cells' membranous organelles, such as exosomes.
Most cell types produce bioactive exosomes, which are 30-100 nm nanovesicles that carry a complex cargo of biomolecules from the original cell. Circulating exosomes are highly stable in biological fluids and therefore provide a great deal of information about the physiological and pathological status of the originating cell. These properties have fulfilled their promise as diagnostic biomarkers, enabling noninvasive clinical diagnosis (Alipoor et al., 2016b).
Numerous recent studies have shown the importance of exosomes and exosomal miRNAs in the fate of TB. It has been shown that the amount and composition of miRNAs packaged into exosomes (exosomal miRNAs) are different in infected versus uninfected macrophages, and also in the serum exosomes from TB patients versus healthy subjects (Hu et al., 2019;Lyu et al., 2019;Biadglegne et al., 2021). Exosomal miRNAs may be useful in the detection and monitoring of tuberculosis, according to these findings.
Despite the advances in understanding the content of Mtb and Mtb-infected host extracellular vesicles, our understanding of the biogenesis and role of extracellular vesicles during Mtb infection is still nascent. Furthermore, understanding the physiology and mechanisms of Mtb, and the mechanisms of orchestration of the host immune system against the bacteria can be interesting research fields to have a better understanding of the pathogenesis of the disease and to improve TB management.
In this Research Topic, we have gathered four studies covering these areas of research.
Mehaffy et al. have reviewed the intricate phenomena of tuberculosis and exosomes, as well as the variations in protein structure, physiology, and interactions with the human host. Extracellular vesicle (EV) capture, kinetics, and purification methods, as well as potential contributions to EV biogenesis in mycobacteria, are effectively discussed in this review.
Fang et al. have shown the role of Rv0790c, a protein encoded by Mtb, in promoting the survival of the bacteria inside the cells. They observed that Rv0790c promotes intracellular mycobacterial life by suppressing cellular autophagy at an early stage following MTB infection. These findings aid in understanding the mechanism of Mtb evasion of host cellular degradation and hold the potential to develop new targets for the prevention and treatment of tuberculosis.
Tian et al. have reviewed the role of cytotoxic T lymphocytes (CTLs) in eliminating intracellular bacteria. They discussed the mechanism of CD4 + /CD8 + CTL differentiation and formation, regulation of key transcription factors, and how CD4 + and CD8 + CTLs kill intracellular bacteria. The authors also describe the application and prospects of these cells in the treatment of intracellular bacterial infections.
Even with current progress in the fundamental research in the field of tuberculosis, we still need to deepen our understanding of the mechanisms of M. tuberculosis as well as the function of the host immune system to find suitable biomarkers and make a breakthrough in TB management, to ultimately meet the goals of the WHO to eradicate TB by 2035.

Author contributions
The author confirms being the sole contributor of this work and has approved it for publication.

Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.